Comparative Pharmacology
Head-to-head clinical analysis: MACROTEC versus TECHNETIUM TC99M MERTIATIDE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROTEC versus TECHNETIUM TC99M MERTIATIDE KIT.
MACROTEC vs TECHNETIUM TC99M MERTIATIDE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable for diagnostic use.
Technetium Tc99m mertiatide is a radiopharmaceutical that undergoes renal tubular secretion and glomerular filtration, allowing imaging of the kidneys. After intravenous administration, it is primarily taken up by the kidneys and excreted into the urine, providing visualization of renal perfusion and function.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
1 mCi (37 MBq) intravenously as a single dose for renal imaging.
None Documented
None Documented
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Terminal elimination half-life: 1.5–2.1 hours (mean 1.8 h). Effective half-life with Tc-99m decay: physical half-life 6.02 h, biological half-life ~1.8 h, effective half-life ~1.4 h. Clinically, imaging completed within 30–60 min post-injection.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Renal: >90% of injected dose excreted via glomerular filtration and tubular secretion within 24 hours. Biliary/fecal: <1%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical